Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buccal Swab Clear all
Recruiting No phase listed Observational

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

NCT06397677
View directory record Official record
Conditions
Rheumatoid Arthritis, Interstitial Lung Disease
Interventions
Research Testing Performed (Laboratory), Information Collected as Standard of Care, Research Testing Performed
Genetic · Diagnostic Test · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 17, 2026, 9:00 AM EDT
Not listed No phase listed Observational

Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

NCT04636775
View directory record Official record
Conditions
NSCLC Stage IV, NSCLC, Recurrent
Interventions
Microbiome
Diagnostic Test
Lead sponsor
Jun Zhang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Fairway, Kansas • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 17, 2026, 9:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects

NCT03748355
View directory record Official record
Conditions
Psychiatric Disorder
Interventions
Pharmacogentic Analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 17, 2026, 9:00 AM EDT
Recruiting No phase listed Observational

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT02269592
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, Hematological Malignancies, B-cell Malignancy, Low-grade, Myelodysplastic Syndrome With Low-grade Lesions, IgG Monoclonal Gammopathy of Uncertain Significance, Smoldering Multiple Myeloma, Waldenstrom Macroglobulinemia
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
7
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 17, 2026, 9:00 AM EDT
Recruiting No phase listed Observational

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

NCT07675967
View directory record Official record
Conditions
Lung Cancer (Diagnosis), Osteochondroma, Spitz Nevus, Solid Cancers, Breast Cancer, Gastric (Stomach) Cancer, Colorectal (Colon or Rectal) Cancer, Sarcoma, Ovarian Adenocarcinoma, Uterine Adenocarcinoma, Endometrial Adenocarcinoma, Esophageal Adenocarcinoma, Head and Neck Cancer, Therapy-Related Acute Myeloid Leukemia, Therapy-Related MDS, Clonal Hematopoiesis of Indeterminate Potential (CHIP), Clonal Cytopenia of Undetermined Significance
Interventions
Samples
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 17, 2026, 9:00 AM EDT
Recruiting No phase listed Observational

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

NCT03555851
View directory record Official record
Conditions
Leukemia, Not Otherwise Specified, Leukemia, Other
Interventions
Cyclophosphamide, Specimen collection
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2035
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 17, 2026, 9:00 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

NCT06577441
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
145
States / cities
Berkeley, California • Irvine, California • Orange, California + 120 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 9:00 AM EDT
Recruiting Not applicable Interventional

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

NCT06943586
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack (TIA)
Interventions
CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
Genetic
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 17, 2026, 9:00 AM EDT
Completed No phase listed Observational

A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia

NCT04255680
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Buccal Swabs and Blood Draws
Diagnostic Test
Lead sponsor
Larimar Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
20 participants
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 17, 2026, 9:00 AM EDT
Completed Not applicable Interventional

Utility of Pharmacogenomic Testing in Patients With Gastrointestinal Disorders

NCT05572593
View directory record Official record
Conditions
Gastrointestinal Diseases
Interventions
Pharmacogenomics (PGx) genetic testing
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 17, 2026, 9:00 AM EDT
Recruiting No phase listed Observational

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

NCT05702645
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
Interventions
Biospecimen Collection, Clinical Evaluation, Neurocognitive Assessment, Questionnaire Administration, Survey Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Years to 39 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Madera, California + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 17, 2026, 9:00 AM EDT
Completed No phase listed Observational

Cancer Detection in Pancreatic Cysts

NCT00222898
View directory record Official record
Conditions
Pancreatic Cyst, Pancreatic Pseudocyst, Pancreatic Neoplasm
Interventions
DNA analysis of pancreatic cyst fluid / buccal swab
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
7
States / cities
Indianapolis, Indiana • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2007 · Synced Oct 17, 2026, 9:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Impact of Vitrification on Oocytes

NCT01223118
View directory record Official record
Conditions
Fertilization
Interventions
Vitrification and PGD
Procedure
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 35 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Morristown, New Jersey • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 17, 2026, 9:00 AM EDT
Active, not recruiting Phase 1 Interventional

CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

NCT03572764
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
CPX-351, Research skin biopsy, Research blood draw, Research bone marrow aspirate
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Tampa, Florida • St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 17, 2026, 9:00 AM EDT
Recruiting Not applicable Interventional

Bright Light Exposure in Surgical Patients

NCT03822949
View directory record Official record
Conditions
Myocardial Ischemia, Critical Illness, Endothelial Dysfunction
Interventions
Day Light, Placebo light, ICU Intense Light, ICU Placebo light
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 17, 2026, 9:00 AM EDT
Terminated Not applicable Interventional

The Role of the Pharmacist and Pharmacogenomics in the Care of Seriously Ill Patients

NCT04251520
View directory record Official record
Conditions
Palliative Medicine
Interventions
Pharmacogenomics testing, Pharmacist review
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 17, 2026, 9:00 AM EDT
Completed No phase listed Observational

Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease

NCT02984059
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Genomic DNA, RNA analysis, Microbiome, Calprotectin, Pain questionnaires, Anxiety/Depression Questionnaires
Genetic · Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 17, 2026, 9:00 AM EDT
Recruiting No phase listed Observational

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

NCT01772771
View directory record Official record
Conditions
Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Melanoma, Sarcoma
Interventions
Biospecimen Collection, Genetic Testing, Medical Chart Review
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 9:00 AM EDT
Recruiting No phase listed Observational

MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome

NCT05937594
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome, Neonatal Abstinence Syndrome
Interventions
Buccal swab saliva for further genetic testing
Genetic
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
1 Day to 5 Days
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 17, 2026, 9:00 AM EDT
Recruiting Not applicable Interventional

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

NCT06630104
View directory record Official record
Conditions
Lymphoproliferative Disorder, Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Electronic Health Record Review, Follow-Up, Genetic Counseling, Genetic Testing
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 9:00 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Vitamin K Supplementation Study in Healthy Volunteers (Aim 2B)

NCT04450212
View directory record Official record
Conditions
Vitamin K Status
Interventions
Phase I, Buccal Swab Collection for DNA Isolation, Phase II, Vitamin K (Vitacost) Supplementation
Genetic · Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 17, 2026, 9:00 AM EDT
Recruiting No phase listed Observational

Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies

NCT05995821
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Gastrointestinal Cancer
Interventions
Collection of biological specimens
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 9:00 AM EDT
Recruiting No phase listed Observational

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

NCT06580106
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Biospecimen samples
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 17, 2026, 9:00 AM EDT
Completed No phase listed Observational

(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation

NCT04811365
View directory record Official record
Conditions
Systemic Mast Cell Activation, KIT D816V Mutation
Interventions
Screening
Other
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 17, 2026, 9:00 AM EDT